Screener / SEC EDGAR /CIK 0000939767 /10-K filed Feb 10, 2026, compared with Feb 11, 2025 /Numbers from the XBRL of the 10-Ks
Health care peers:
Nasdaq Health care · Biotechnology

Exelixis, Inc. EXEL

Exelixis, Inc. (Exelixis, we, our or us) is an oncology company innovating next-generation medicines and regimens at the forefront of cancer care. 10-K, Item 1

Employees
1,077
Headquarters
Alameda, CA
CEO
Michael Morrissey
Next results
around Jan 11, 2027
Compare with peers Embed

Where each dollar of revenue went, FY2025

Revenue of $2.3B through the costs to a net profit of $782.6M · income statement of the 10-K

38% operating margin
Revenue to Gross profit: $2.2BRevenue to Cost of revenue: $83.7MGross profit to Operating profit: $872.2MGross profit to Operating expenses: $1.4BOperating profit to Net profit: $713.6MOperating profit to Tax: $158.6MOther income to Net profit: $69.0MOperating expenses to R&D: $825.0MOperating expenses to Sales, admin & other: $539.2M Revenue: $2.3B REVENUE $2.3B +7% Y/Y Gross profit: $2.2B · 96% margin GROSS PROFIT $2.2B 96% margin Cost of revenue: $83.7M · 4% of revenue COST OF REVENUE $83.7M 4% of revenue Operating profit: $872.2M · 38% margin OPERATING PROFIT $872.2M 38% margin · +44% Y/Y Other income: $69.0M · 3% of revenue OTHER INCOME $69.0M 3% of revenue Operating expenses: $1.4B · 59% of revenue OPERATING EXPENSES $1.4B 59% of revenue Net profit: $782.6M · 34% margin NET PROFIT $782.6M 34% margin · +50% Y/Y Tax: $158.6M · 7% of revenue TAX $158.6M 7% of revenue R&D: $825.0M · 36% of revenue R&D $825.0M 36% of revenue Sales, admin & other: $539.2M · 23% of revenue SALES, ADMIN & OTHER $539.2M 23% of revenue
Gross profit $2.2B 96% margin
Operating profit $872.2M 38% margin · +44% Y/Y
Net profit $782.6M 34% margin · +50% Y/Y
The full income statement, year by year

EXEL among Health care peers

Six ratios from the latest 10-K. Each corner is the share of 154 peers the company is above, not a score.

Compare
Revenue growth: 7.0%, above 36% of 154 peers (their median 10.5%) REVENUE GROWTH 7.0% · above 36% Gross margin: 96.3%, above 99% of 107 peers (their median 63.4%) GROSS MARGIN 96.3% · above 99% Operating margin: 40.2%, above 96% of 138 peers (their median 9.8%) OPERATING MARGIN 40.2% · above 96% Net margin: 35.5%, above 97% of 153 peers (their median 6.7%) NET MARGIN 35.5% · above 97% FCF margin: 46.5%, above 99% of 144 peers (their median 9.9%) FCF MARGIN 46.5% · above 99%
EXEL Peer median Below the median

What changed

12 new risk paragraphs. 10-K filed Feb 10, 2026 against Feb 11, 2025.

Each row opens the detail with the quote and the filing. A row is a change worth reading, not a verdict.

Accounting checks

11 checks on the latest 10-K. Checks, not verdicts.

How it works

0facts worth reading about all 11 checks found nothing to note

  • Receivables +8.1% ($265.4M to $286.9M) vs revenue +7.0% ($2.2B to $2.3B), +1.1 pts apart
  • Cash from operations $884.3M vs net income $782.6M (FY ending Jan 2, 2026)
  • Inventory -3.1% ($22.4M to $21.7M) vs revenue +7.0% ($2.2B to $2.3B), -10.1 pts apart
8 more checks with nothing to note
  • Same auditor in both 10-Ks: Ernst & Young LLP
  • No statement of substantial doubt about going concern
  • No 8-K item 4.02 in the last 2 years
  • No NT 10-K or NT 10-Q in the last 2 years
  • No longer listed: Table of C o n t e n t s. Same as last year: Net product revenues
  • No sentence in the 10-K concludes that controls were not effective because of a material weakness
  • No 8-K item 2.06 in the last 2 years
  • No 8-K item 1.03 in the last 2 years

In their words

12 paragraphs in Risk Factors that were not in the 10-K filed Feb 11, 2025. Quoted as filed.

All 12 new paragraphs
  1. Item 1A · new paragraph · not in the 10-K filed Feb 11, 2025 10-K, ITEM 1A
    We anticipate that for the foreseeable future, our ability to maintain or meaningfully increase cash flow to fund our business operations and growth will depend upon the continued commercial success of CABOMETYX, both alone and in
  2. Item 1A · new paragraph · not in the 10-K filed Feb 11, 2025 10-K, ITEM 1A
    Concern over access to and affordability of pharmaceutical products continues to spur debate and action by U.S. federal and state government authorities in an effort to contain healthcare costs. Such proposals and actions include: •use of mandated discounts, rebates, restrictive formularies, or other reference-based price controls, such…
  3. Item 1A · new paragraph · not in the 10-K filed Feb 11, 2025 10-K, ITEM 1A
    In addition, the current U.S. administration has indicated that it plans to pursue additional policies aimed at lowering prescription drug costs. For example, on May 12, 2025, the current administration published an executive order that expressed support for equalizing the prices paid for drugs in the United States and other developed…
  4. Item 1A · new paragraph · not in the 10-K filed Feb 11, 2025 10-K, ITEM 1A
    On March 17, 2025, April 24, 2025, and May 27, 2025, we received notice letters (collectively, Notices) from the West Virginia Board of Pharmacy (WV Board) of complaints filed against us for purported violations of laws related to distribution of drugs to 340B facilities (West Virginia Code § 60A-8-6a (WV Statute)). The WV Statute…

New risk paragraphs, against peers

Latest 10-K of each, Health care companies closest in revenue

Paragraphs in Risk Factors with nothing like them in the company's 10-K the year before. A count of text, not of risk.

Financial performance

Last 4 fiscal years · 10-K XBRL

All years
MetricFY2022FY2023FY2024FY2025
Revenue$1.6B$1.8B$2.2B$2.3B
Net income$182.3M$207.8M$521.3M$782.6M
Operating cash flow$362.6M$333.3M$700.0M$884.3M
Free cash flow$334.9M$292.9M$671.5M$875.8M

Revenue, FY2016 to FY2025

Ten fiscal years, each from its own 10-K · XBRL · USD

$2.3B ▲ 7.0% in FY2025

FY2016FY2017FY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025
Every number, year by year

Recent filings

2 filings in the last 30 days · SEC EDGAR

All filings

About the company

Exelixis, Inc., Alameda, CA · from the 10-K filed Feb 10, 2026

Exelixis, Inc. (Exelixis, we, our or us) is an oncology company innovating next-generation medicines and regimens at the forefront of cancer care. We have produced four marketed pharmaceutical products, two of which are formulations of our flagship molecule, cabozantinib, and we are steadily advancing and evolving our product pipeline portfolio, including our lead clinical asset, zanzalintinib, currently under review by the U.S. Food and Drug Administration (FDA) for the treatment of certain forms of colorectal cancer (CRC), as well as the focus of an extensive late-stage clinical development program in other indications.

Headquarters
Alameda, CA
Country
United States
Reports in
USD
Listed on
Nasdaq
Fiscal year ends
January 1
Last results
Oct 29, 2026
Incorporated in
DE

Employees, at the top of the page: "As of December 31, 2025, we had 1,077 employees, representing a 6" (10-K). Address and exchange: SEC's company file.

Email alerts

Sources

The 10-K filed Feb 10, 2026 (open at SEC), compared with the 10-K filed Feb 11, 2025. Numbers from the XBRL of the 10-Ks; filings from SEC EDGAR.

Work with it: Excel workbook · CSV. Google Sheet that stays up to date: paste =IMPORTDATA("https://tickdelta.com/company/EXEL/export.csv") into a cell.

Esc

Type a ticker such as AAPL, a name, an investor such as Buffett, or a topic such as tariffs. ↑ ↓ to move, Enter to open.